Home - National Multiple Sclerosis Society

Skip to navigation Skip to content
National MS Society
Email not displaying correctly? View it in your browser.
National MS Society eNews - July 2010
FDA Supports fact track for Alemtuzumab

Alemtuzumab poised for quick review

Alemtuzumab, an IV treatment for relapsing-remitting MS, will head into expedited FDA review as soon as the current Phase III trial is completed. Learn more

For details on the therapeutic effects and adverse side effects of this treatment, see Dr. Loren Rolak’s report in our June 30 webcast, “What’s new in MS research and treatment.” Dr. Rolak’s presentation begins four-and-a-half minutes into the program. View webcast

Donate Now

 Find us on Facebook 

YouTube MySpace Twitter


Meet

 

Meet Tamara Carpenter

Tamara Carpenter sparks MS awareness

Imani Radney

Imani Radney, recipient of
4-year Presidential Scholarship

View 

 The 22 top Society scholarship recipients

The 22 top Society
scholarship recipients

 

Health care reform bill is bringing changes Health Care Reform bill is bringing changes

Changes in access to health insurance and new health insurance rules are starting now with more to come this fall and next January. What does this mean to you? Our Health Care Reform team has created concise answers to the FAQs of people affected by MS.

See them here

 

Free access to milestone MS research papersFree access to milestone MS research papers
From now to mid-September, see pivotal research papers FREE through a partnership among Fast Forward, the Society and Nature Publishing Group. Download papers on current work in stem cell transplantation, MS risk factors, neuroprotection and repair, and more.

Find out how

 

Watch the recorded webcastJune 30 webcast on the coming era in MS treatment
Three noted MS investigators answered what, why, and when questions about new oral and infrequent dosing MS therapies, nervous system protection and repair, and the status of and new projects focused on CCSVI research.

Video and transcript available here

 


This communication is partially sponsored through the generous support of Bayer HealthCare and Teva Pharmaceuticals, Inc.

Bayer HealthCare       Teva Pharmaceuticals, Inc.

More MS News
June 11: Over $2.4 million committed to CCSVI research projects
May 25: Fast Forward and Five Prime Therapeutics collaborate on new molecule that may benefit progressive as well as relapsing MS
Read more about these and other recent reports
Shop at the Society Store       Join a Walk MS Event       Join a Bike MS Event

National MS Society | View as Web page | Subscribe | Legal Notice/Privacy Policy | Email Preferences | Unsubscribe

MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS.
JOIN THE MOVEMENT®

Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please
visit our Web site.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.

National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017

This message was sent to . To ensure that you continue to receive our emails, please add us to your address book.